ConductScience.org, home

Paper29043232

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.

Yoon JH and 15 others. Blood Res, 2017. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia. Papers, record 29043232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29043232

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.
PubMed
Journal
Blood Res
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.28
iCite
Revised in PubMed
2024-03-27
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yoon JHJae-Ho
2Kim HJHee-Je
3Kwak DHDae-Hun
4Min GJGi June
5Park SSSung-Soo
6Jeon YWYoung-Woo
7Lee SESung-Eun
8Cho BSByung-Sik
9Eom KSKi-Seong
10Kim YJYoo-Jin
11Lee SSeok
12Min CKChang-Ki
13Cho SGSeok-Goo
14Kim DWDong-Wook
15Lee JWJong Wook
16Min WSWoo-Sung

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110502596Acute myeloid leukemia.N Engl J Med1999https://conductscience.org/library/papers/10502596PubMed
228089879Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?Biol Blood Marrow Transplant2017https://conductscience.org/library/papers/28089879PubMed
312393605
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Blood2003https://conductscience.org/library/papers/12393605PubMed
48558199
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
J Clin Oncol1996https://conductscience.org/library/papers/8558199PubMed
520694843
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
Int J Hematol2010https://conductscience.org/library/papers/20694843PubMed
625300871
A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Biol Blood Marrow Transplant2015https://conductscience.org/library/papers/25300871PubMed
78078551Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.N Engl J Med1994https://conductscience.org/library/papers/8078551PubMed
820048183
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
J Clin Oncol2010https://conductscience.org/library/papers/20048183PubMed
98634416A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.Blood1996https://conductscience.org/library/papers/8634416PubMed
1025833957A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Blood2015https://conductscience.org/library/papers/25833957PubMed
1126663264Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?Am J Hematol2016https://conductscience.org/library/papers/26663264PubMed
129517503Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.Leuk Lymphoma1998https://conductscience.org/library/papers/9517503PubMed
1322287757A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.Anticancer Res2012https://conductscience.org/library/papers/22287757PubMed
1421828126A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.Blood2011https://conductscience.org/library/papers/21828126PubMed
1523398482Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.Br J Haematol2013https://conductscience.org/library/papers/23398482PubMed
1615075074A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.Haematologica2004https://conductscience.org/library/papers/15075074PubMed
173702507Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.Med Oncol Tumor Pharmacother1986https://conductscience.org/library/papers/3702507PubMed
188874180A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.Blood1996https://conductscience.org/library/papers/8874180PubMed
198916313
Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Semin Hematol1996https://conductscience.org/library/papers/8916313PubMed
2028687581Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2017https://conductscience.org/library/papers/28687581PubMed

See all 28 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42583229
Venetoclax plus azacitidine, low-dose cytarabine, aclarubicin, and G-CSF (VA-CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single-arm Phase II clinical trial.
Hemasphere2026https://conductscience.org/library/papers/42583229PubMed
38023260Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML.Front Oncol2023https://conductscience.org/library/papers/38023260PubMed
37762881Machine Learning Predicts 30-Day Outcome among Acute Myeloid Leukemia Patients: A Single-Center, Retrospective, Cohort Study.J Clin Med2023https://conductscience.org/library/papers/37762881PubMed
36874817Effects of different psychological interventions on quality of life and remission rate in patients with acute leukemia receiving chemotherapy: A randomized controlled trial.Front Psychol2023https://conductscience.org/library/papers/36874817PubMed
29848341Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.J Hematol Oncol2018https://conductscience.org/library/papers/29848341PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29043232

GET https://conductscience.org/api/papers/v1/29043232/references?page=2